Andere Sprachen Stoke Therapeutics, Inc.

Aktien

A2PLTL

US86150R1077

STOK

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
12.41 ^USD	+6.16%		+2.99%	+135.93%

17.04.	Stoke Therapeutics ernennt Jason Hoitt zum Chief Commercial Officer	CI
28.03.	Sektor-Update: Aktien des Gesundheitswesens steigen am Donnerstag vorbörslich	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	17.04.
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	17.04.
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	04.04.
Sector Update: Health Care Stocks Advance Premarket Thursday	28.03.
Stoke Therapeutics Prices Upsized $125 Million Share Offering	28.03.
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering	28.03.
North American Morning Briefing : Stocks Edge -2-	27.03.
Stoke Therapeutics Plans $75 Million Public Offering	26.03.
Stoke Therapeutics Announces Proposed Public Offering	26.03.
Sector Update: Health Care Stocks Advance Late Afternoon	26.03.
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients	26.03.
Top Midday Gainers	26.03.
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26.03.
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	26.03.
Top Premarket Gainers	26.03.
North American Morning Briefing : Markets Steady as Traders Eye Next Inflation Gauge	26.03.
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	25.03.
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome	25.03.
Stoke Therapeutics, Inc Announces New Data that Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome	25.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Stoke Therapeutics, Inc.

Aktien

A2PLTL

US86150R1077

STOK

Andere Sprachen

Filter